Apr23Sat

News from the Cork Chamber

Commencement of Port of Cork Container Terminal operations in Ringaskiddy will enhance international
Cork Chamber

– Customs and regional infrastructure is vital to continued growth-

Cork Chamber are pleased to welcome the commencement of operations at the Port of Cork’s new €86m Container Terminal in Ringaskiddy tomorrow.

Commenting on the announcement, Paula Cogan, President, Cork Chamber said, “This significant moment for Cork will build upon the already strong trade links between the Port of Cork and the US, and ultimately bring some peace of mind in the context of the global supply-chain and international trade instability we are facing.”

“This strategic enhancement for our city region and country highlights the value of our marine infrastructure. It is now vital that the Government supports border and customs inspection infrastructure at the Port, alongside the enhanced delivery of M28 in order to facilitate this continued expansion, advance connectivity, and signal to investors the visionary and globally competitive nature of Cork.”

Apr22Fri

News from 2022 Ambassador Award Honoree

New Cork Container Terminal Commences Operations
Business Plus

Port of Cork Company celebrates a significant milestone as the €86 million Cork Container Terminal (CCT) becomes operational in Ringaskiddy this Saturday 23rd, April. It represents the largest single investment in marine infrastructure in its history and the largest investment of any Irish port over the last 100 years.

The Port of Cork Company‘s new Cork Container Terminal in Ringaskiddy, billed as the largest investment of any Irish port in over a century, will commence operations this weekend. .

The long-awaited launch of CCT will enable the semi-state company to more efficiently handle containers and potentially increase trade and facilitate regional and national economic growth.

CCT will initially handle ICL‘s Cork to US service as well as the weekly Maersk Costa Rican service as Port of Cork continues the process of relocating its deep-sea trans-ocean cargo business to the site.

“This is a proud and monumental milestone for our people and our business. CCT is the largest investment in our 250 year history,” said Conor Mowlds, chief commercial officer. “It’s a pivotal project in our strategic efforts to enhance and future proof our offering which will position Cork as an international gateway for trade.”

Port of Cork reported traffic throughput of 10.5m tonnes in 2020, and the terminal forms part of its long-term strategic effort to enhance and futureproof its offering while positioning itself as an international gateway for trade.

Some 35 of the company’s top customers from industries such as medtech, pharma, IT, chemical and agri-food account for €145m of manufacturing output, and support over 45,000 jobs in the south-west region.

Cork Port is the world’s second largest natural harbour. The multi-modal port is also one of only two Irish ports to service all six shipping modes: lift-on/lift-off, roll-on/ roll-off, liquid bulk, dry bulk, break bulk and cruise.

The CCT launch takes place a day after Rosslare Europort announced plans to turn the port and its environs into a renewable energy hub for offshore wind, aligning with existing development plans as part of a total combined investment of €350m.

https://businessplus.ie/news/port-of-cork-container-terminal/

The Port of Cork, ICL and Penn Terminals received the Irish Chamber’s 2022 Ambassador Award.

Apr19Tue

News from Amicus Therapeutics

News from a former Ambassador Award Honoree: Amicus Therapeutics Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038

Galafold U.S. Intellectual Property Protection Now Includes 35 Issued Patents, 18 of which expire in 2038

PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,304,940, which is directed to a composition of matter covering migalastat (Galafold®).

The new U.S. patent titled “Methods of Treating Fabry Patients Having Renal Impairments” is directed to a molecule comprising migalastat bound to an alpha-galactosidase A protein and expires in 2038.

Read More

Apr13Wed

Member News from Acumen Analytics

Acumen Analytics Launches ‘Life Sphere’ A New Podcast Dedicated to the People in Life Sciences.

The podcast features experts and advocates discussing trends, tools, careers and all components of the Life Sciences industry.

The first episodes of season one will be available May 3. New episodes will be released on Tuesdays. To learn more about Life Sphere, check the Acumen website for more details as they become available https://acumenanalytics.com/news/

Apr08Fri

Board Member News

Irish Chamber Board Member, Eric Karas, is a recognized commercial leader in the biopharmaceutical industry with more than 25 years of sales, marketing, market access, and strategic planning experience across multiple specialty product launches.

Mr. Karas was recently appointed Chief Commercial Officer with ARS Pharma.  Prior he was Vice President & General Manager of Commercial, North America at Emergent BioSolutions. He also led commercial initiatives for NARCAN® Nasal Spray at Adapt Pharmaceutical, which was acquired by Emergent in 2018. Before Adapt Pharmaceutical, Mr. Karas was credited with being at the forefront of Auxilium Pharmaceuticals’ growth during his 8-year tenure and overseeing all global commercial objectives related to its urology portfolio. He also led the launch readiness planning and go-to-market strategy for the launch of XIAFLEX® for Peyronie’s disease. Auxilium was acquired in 2015 by Endo Pharmaceuticals.

Mr. Karas also has held cross-functional roles in government affairs, public relations, patient advocacy, and sales leadership roles at Astellas, Bristol-Myers Squibb, and Merck. Industry associations have also recognized him for numerous disease awareness and branded campaigns targeting HCPs and consumers.

Mr. Karas received his MBA in Integrated Management from Michigan State University, Broad School of Management, and a Bachelor of Science in Accounting from Rutgers University.